WASHINGTON — It’s a rite of passage for executives in the hot seat: get hauled before Congress, sit for bipartisan tirades, squirm in the face of difficult questioning.

Over the past six months, lawmakers have dragged in former Equifax CEO Richard Smith, Wells Fargo’s Tim Sloan, and Amtrak’s Richard Anderson. Facebook’s Mark Zuckerberg could be the next one up.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • seriously? i think you’re misinformed.

    why haven’t pharma CEOs been investigated by the SEC and other governmental bodies? see: Bresch at Mylan, Pearson at Valeant and of course our favorite Shkreli at Turing.

    is that not enough? or are you suggesting that other CEOs are guilty of outrageous behavior and/or fraud?

    newsflash: CEOs are paid to deliver returns to investors, not to look saintly in the eyes of journalists.

    • I agree with Mr. King’s point. Congress did vet both Pearson and Shkreli heavily. Maybe the history is not as strong or tough as it should be. But it has not been been ignored as suggested.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy